Journal
ONCOTARGETS AND THERAPY
Volume 13, Issue -, Pages 11019-11029Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S268851
Keywords
oral squamous cell carcinoma; metformin; 4SC-202; invasion; migration
Categories
Funding
- National Natural Science Foundation of China [81671000, 81870769]
- Science and Technology Program of Guangzhou, China [201803010019, 201607010354]
Ask authors/readers for more resources
Background: Oral squamous cell carcinoma (OSCC), the most common epithelial malignant neoplasm in the head and neck, characterizes with local infiltration and metastasis of lymph nodes. The five-year survival rate of OSCC remains low despite the advances in clinical methods. Thus, it is necessary to develop a new effective therapeutic scheme for OSCC. Our previous results showed that metformin and 4SC-202 synergistically promoted the intrinsic apoptosis of OSCC in vitro and in vivo, but the effects on invasion and migration remained unclear. Methods: Human OSCC cell lines HSC6 and CAL33 were cultured with metformin (16 mM) or/ and 4SC-202 (0.4 WI for 72 h. STAT3 inhibitor S31-201 was applied at concentration of 60 nM for 48 h. Wound-healing assays and transwell assays were used to determine the invasion and migration ability of OSCC. qRT-PCR and Western blot were performed to detect mRNA levels and protein levels. Results: Metformin or/and 4SC-202 suppressed the migration and invasion of OSCC cells. Importantly, the expression of TWIST1 was suppressed by metformin and 4SC-202, while the invasion and migration inhibitory effects of metformin and 4SC-202 were countered by the overexpression of TWIST1. In addition, the phosphorylation level of STAT3 decreased after the administration of metformin or/and 4SC-202. Furthermore, inhibition of STAT3 by S31-201 suppressed the expression of TWIST1 and led to a decline in migration and invasion of OSCC, while overexpression of TWIST1 attenuated these effects. Conclusion: Metformin and 4SC-202 suppressed the invasion and migration of OSCC through inhibition of STAT3/TWIST1, and this scheme can serve as a novel therapeutic strategy for OSCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available